Characteristics of small breast and/or ovarian cancer families with germline mutations in BRCA1 and BRCA2

被引:0
|
作者
M J L Ligtenberg
F B L Hogervorst
H W Willems
P J W Arts
G Brink
S Hageman
E A J Bosgoed
E Van der Looij
M A Rookus
P Devilee
E M A W Vos
G Wigbout
P M Struycken
F H Menko
E J Th Rutgers
E H Hoefsloot
E C M Mariman
H G Brunner
L J Van’t Veer
机构
[1] University Hospital Nijmegen,Department of Human Genetics
[2] University Hospital Nijmegen,Department of Pathology
[3] The Netherlands Cancer Institute,Department of Pathology and The Family Cancer Clinic
[4] Plesmanlaan 121,Department of Epidemiology
[5] The Netherlands Cancer Institute,Department of Human Genetics and Department of Pathology
[6] Plesmanlaan 121,Department of Clinical Genetics
[7] University of Leiden,undefined
[8] Family Cancer Clinic,undefined
[9] University Hospital Vrije Universiteit,undefined
来源
British Journal of Cancer | 1999年 / 79卷
关键词
breast cancer; ovarian cancer; bilateral breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
For families with a small number of cases of breast and/or ovarian cancer, limited data are available to predict the likelihood of genetic predisposition due to mutations in BRCA1 or BRCA2. In 104 families with three or more affected individuals (average 3.8) seeking counselling at family cancer clinics, mutation analysis was performed in the open reading frame of BRCA1 and BRCA2 by the protein truncation test and mutation-specific assays. In 31 of the 104 families tested, mutations were detected (30%). The majority of these mutations (25) occurred in BRCA1. Mutations were detected in 15 out of 25 families (60%) with both breast and ovarian cancer and in 16 out of 79 families (20%) with exclusively cases of breast cancer. Thus, an ovarian cancer case strongly predicted finding a mutation (P < 0.001). Within the group of small breast-cancer-only families, a bilateral breast cancer case or a unilateral breast cancer case diagnosed before age 40 independently predicted finding a BRCA1 or BRCA2 mutation (P = 0.005 and P = 0.02, respectively). Therefore, even small breast/ovarian cancer families with at least one case of ovarian cancer, bilateral breast cancer, or a case of breast cancer diagnosed before age 40, should be referred for mutation screening.
引用
收藏
页码:1475 / 1478
页数:3
相关论文
共 50 条
  • [41] Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations
    Thomas v. O. Hansen
    Lars Jønson
    Ane Y. Steffensen
    Mette K. Andersen
    Susanne Kjaergaard
    Anne-Marie Gerdes
    Bent Ejlertsen
    Finn C. Nielsen
    Familial Cancer, 2011, 10 : 207 - 212
  • [42] BRCA1 and BRCA2 founder mutations account for 78% of germline carriers among hereditary breast cancer families in Chile
    Alvarez, Carolina
    Tapia, Teresa
    Perez-Moreno, Elisa
    Gajardo-Meneses, Patricia
    Ruiz, Catalina
    Rios, Mabel
    Missarelli, Claudio
    Silva, Mariela
    Cruz, Adolfo
    Matamala, Luis
    Carvajal-Carmona, Luis
    Camus, Mauricio
    Carvallo, Pilar
    ONCOTARGET, 2017, 8 (43) : 74233 - 74243
  • [43] Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
    Dorra Ben Ayed-Guerfali
    Wala Ben Kridis-Rejab
    Nihel Ammous-Boukhris
    Wajdi Ayadi
    Slim Charfi
    Afef Khanfir
    Tahia Sellami-Boudawara
    Mounir Frikha
    Jamel Daoud
    Raja Mokdad-Gargouri
    Journal of Translational Medicine, 19
  • [44] BRCA1 and BRCA2 Genetic Testing in Breast and/or Ovarian Cancer Families in Iran
    Keshavarzi, Fatemeh
    Javadi, Gholam Reza
    Nafissi, Nahid
    Akbari, Mohammad Esmail
    Yassaee, Vahid Reza
    Farzad, Maryam Sharafi
    Zeinali, Sirous
    YAKHTEH, 2010, 12 (03): : 329 - 340
  • [45] Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel
    Laitman, Yael
    Simeonov, Monica
    Herskovitz, Liron
    Kushnir, Anya
    Shimon-Paluch, Shani
    Kaufman, Bella
    Zidan, Jamal
    Friedman, Eitan
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (03) : 1153 - 1157
  • [46] Germline variants profiling of BRCA1 and BRCA2 in Chinese Hakka breast and ovarian cancer patients
    Zhang, Yunuo
    Wu, Heming
    Yu, Zhikang
    Li, Liang
    Zhang, Jinhong
    Liang, Xinhong
    Huang, Qingyan
    BMC CANCER, 2022, 22 (01)
  • [47] Novel and recurrent BRCA1/BRCA2 germline mutations in patients with breast/ovarian cancer: a series from the south of Tunisia
    Ben Ayed-Guerfali, Dorra
    Ben Kridis-Rejab, Wala
    Ammous-Boukhris, Nihel
    Ayadi, Wajdi
    Charfi, Slim
    Khanfir, Afef
    Sellami-Boudawara, Tahia
    Frikha, Mounir
    Daoud, Jamel
    Mokdad-Gargouri, Raja
    JOURNAL OF TRANSLATIONAL MEDICINE, 2021, 19 (01)
  • [48] Prevalence and Penetrance of BRCA1 and BRCA2 Germline Mutations in Colombian Breast Cancer Patients
    Torres, D.
    Bermejo, J. Lorenzo
    Rashid, M. U.
    Briceno, I.
    Gil, F.
    Beltran, A.
    Ariza, V.
    Hamann, U.
    SCIENTIFIC REPORTS, 2017, 7
  • [49] Germline BRCA1 and BRCA2 mutations and the risk of bladder or kidney cancer in Poland
    Zlowocka-Perlowska, Elzbieta
    Toloczko-Grabarek, Aleksandra
    Narod, Steven A.
    Lubinski, Jan
    HEREDITARY CANCER IN CLINICAL PRACTICE, 2022, 20 (01)
  • [50] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150